Related by context. All words. (Click for frequent words.) 65 cardiometabolic disorders 64 lipid disorders 64 cardio metabolic 62 glucokinase activator 61 INS# [001] 61 cardiometabolic risk 61 dyslipidemias 61 Nanobody ® 61 immunology oncology 60 romazarit 60 rheumatic diseases 60 ONCONASE R 60 endocrine diseases 59 atherogenic dyslipidemia 59 tiapamil 59 immunological diseases 58 Archexin 58 cardio renal 58 PSN# [001] 58 resolvins 58 orally bioavailable mimics 58 cardiovascular metabolic 58 lomitapide 58 clevidipine 58 Meridia sibutramine 58 diarrhea predominant irritable 58 immune modulating 58 triglyceride lowering 57 CB1 antagonists 57 primary hyperparathyroidism 57 kidney urologic 57 metabolic disorders 57 PHX# 57 cardio metabolic diseases 57 Aurora kinase inhibitors 57 dermatologic diseases 57 cardiovascular 57 obesity insulin resistance 57 neurology oncology 57 ATL/TV# 57 ulimorelin 57 neuropsychiatric diseases 57 immunotherapeutic approaches 57 non alcoholic steatohepatitis 57 thetreatment 57 genomic biomarker 57 lipohypertrophy 57 davalintide 57 SNT MC# 57 PSN# [002] 57 pharmacological therapies 57 immunotherapeutic vaccine 56 eprotirome 56 DDP# 56 RNAi therapeutic targeting 56 Squalamine 56 autoimmune inflammatory 56 ularitide 56 thrombotic diseases 56 HeFH 56 PDE# inhibitors 56 SAR# [002] 56 investigational therapies 56 Pimavanserin 56 Nanobody 56 endothelin antagonist 56 secondary hyperparathyroidism 56 cardiometabolic diseases 56 SILENOR 56 BXT # 56 gastrointestinal GI disorders 56 diabetic nephropathy 56 therapeutic peptide 56 Cinquil 56 metaglidasen 56 ophthalmology oncology 56 selective androgen receptor modulators 56 Rheumatoid Arthritis RA 56 lipid parameters 56 Dyslipidemia 56 including eniluracil ADH 56 LibiGel ® 56 GPR# agonist 56 macrovascular events 56 YONDELIS R 56 atrasentan 56 selective androgen receptor modulator 56 Oglemilast 55 gastrointestinal GI 55 dyslipidaemia 55 neuronal nicotinic receptors NNRs 55 dyslipidemia 55 anti amnesic 55 diabetic microvascular complications 55 oncology urology 55 Zemiva TM 55 Colostrinin 55 rxRNA 55 R#/MEM 55 pharmacologic treatments 55 companion diagnostics 55 cannabinor 55 epilepsy Parkinson disease 55 diabetes dyslipidemia 55 direct thrombin inhibitors 55 prostone 55 davunetide intravenous AL 55 insulin resistance syndrome 55 Bicifadine 55 CCR9 antagonist 55 GI motility disorders 55 cardiac repolarization 55 cancer cachexia 55 CINOD 55 leukotriene pathway 55 immunological disorders 55 Oncology Primary Care 55 dermatological diseases 55 hypercholesterolaemia 55 XP #L 55 nonalcoholic steatohepatitis 55 metabolic parameters 55 adipiplon 55 diagnostic biomarkers 55 endocrinologic 55 NTDDS 55 clinically validated 55 CEQ# 55 hyperlipidaemia 55 ELND-#/AZD-# 55 Trofex TM 55 EGS# 55 neuro inflammatory 55 sodium thiosulfate STS 55 Urocortin 2 55 NP2 Enkephalin 55 EP #R 55 SYN# 55 Solazed TM 55 monoclonal antibody therapeutics 55 renal anemia 55 nociceptive pain 55 Azedra TM 55 thrombo embolic 55 hyperlipidemia 55 ORENCIA R 55 cachexia anti infectives 55 schizophrenia CIAS 55 CB2 receptor selective 55 ERYtech 55 haematological cancers 55 insulin analogs 55 peptide therapeutics 55 arterial hypertension 54 teplizumab 54 musculoskeletal diseases 54 blood coagulation disorders 54 LUNESTA ® 54 PPAR agonist 54 ibudilast 54 RhuDex ® 54 dextofisopam 54 PGL# 54 hormone therapy HT 54 chronic renal disease 54 Mesafem 54 biomarker identification 54 Optiquel ™ 54 JAK inhibitors 54 Prodarsan ® 54 antithrombotics 54 Cetrorelix 54 THALOMID 54 Asthma COPD 54 pathogenetic 54 Hypertriglyceridemia 54 TLR antagonists 54 post surgical adhesions 54 hypertension osteoarthritis 54 lipid lowering agents 54 EHT AGN 54 myopathy rhabdomyolysis 54 acute coronary syndromes ACS 54 chronic thromboembolic pulmonary 54 G6PD deficiency 54 midstage clinical 54 Supernus Pharmaceuticals 54 NOX E# 54 oral RSD# 54 mGluR2 NAM 54 Cleviprex TM clevidipine 54 postoperative ileus 54 DeveloGen 54 cardiovascular metabolic diseases 54 oncology endocrinology 54 atacicept 54 Prodarsan R 54 interventional therapies 54 gynecological diseases 54 Syncria R 54 Alzheimer disease cognitive impairment 54 Virulizin ® 54 Neurodegenerative diseases 54 NNR Therapeutics 54 RELOVAIR ™ 54 J. Donald deBethizy 54 elevated uric acid 54 neovascular diseases 54 mechanistic studies 54 either acutely decompensated 54 insulin analogues 54 pharmacodynamic parameters 54 Safinamide 54 pharmacotherapeutic 54 immuno modulatory 54 vivo pharmacology 54 pharmacotherapies 54 protein misfolding diseases 54 fibromyalgia syndrome 54 PDE4 inhibitor 54 aesthetic dermatology 54 gepirone ER 54 dexanabinol 54 diabetes hyperlipidemia 54 lexidronam injection 54 DCCR 54 Metabolic Disorders 54 droxidopa 54 BEMA TM Fentanyl 54 ISIS # 54 HCV protease inhibitors 54 liprotamase 54 myelofibrosis polycythemia vera 54 elevated triglycerides 54 antihypertensive therapy 54 biologic therapeutics 54 AERx iDMS 54 immuno inflammatory diseases 54 Mipomersen 54 Liprotamase 54 Metabolic Syndrome 54 constipation OIC 54 therapeutic monoclonal antibodies 54 MEK inhibitors 54 psoriatic arthritis PsA 54 oral prodrug 54 abnormal lipids 54 dopaminergic therapy 54 Celacade TM 54 aripiprazole Abilify 54 inflammatory autoimmune diseases 54 atherothrombosis 54 benign prostatic hypertrophy BPH 54 GLPG# 54 NovaBay Aganocide compounds 54 ALN PCS 54 cardiovascular anti infectives 54 neuropathic pain metabolic diseases 54 Zometa zoledronic acid 54 CNS disorders 54 Secondary efficacy endpoints 54 clinical pharmacology studies 54 intranasal insulin product 54 overt nephropathy 54 TKM ApoB 54 Androxal TM 54 CAPHOSOL 54 pioglitazone HCl 53 Pyridorin 53 ADME properties 53 oncology cardiology 53 clinical 53 MAXY VII 53 prenatal exposures 53 deforolimus 53 RNAi therapeutic targeting PCSK9 53 p# inhibitor 53 PAOD 53 purinergic receptors P#X# 53 candidate CRLX# 53 zileuton 53 rosuvastatin Crestor 53 LHRH antagonists 53 Cx# [002] 53 oncology immunology 53 RhuDex 53 diseases fat malabsorption 53 radionuclide therapy 53 Rebif ® 53 Symadex 53 Hypercholesterolemia 53 diabetes cardiovascular disease 53 Valsartan 53 metformin Glucophage 53 hypercholesterolemia 53 respiratory gastrointestinal 53 MYCAMINE 53 predictive toxicology 53 investigational compounds 53 Metabolic Disease 53 thiazolidinedione TZD 53 cardiovascular disease osteoporosis 53 microplasmin Phase III 53 antidiabetic drugs 53 neuropsychiatric disorders 53 Ketotransdel TM 53 FOLOTYN ® 53 riociguat 53 pharmacoeconomic 53 Gag polymorphisms 53 synthetic retinoid 53 luliconazole 53 dyslipidemic 53 ocular disorders 53 Savella TM 53 valvular heart 53 trospium 53 gastro intestinal inflammation 53 macular degeneration diabetic retinopathy 53 TRIOLEX HE# 53 neuroprotective agent 53 Hematide ™ peginesatide 53 phase IIb trial 53 pharmacogenetic testing 53 postmarketing adverse 53 ERYtech Pharma 53 leading oral taxane 53 6R BH4 53 REG1 53 Novolimus 53 oncology virology 53 Firazyr ® 53 JAK2 inhibitor 53 Rezular 53 vitro diagnostics IVD 53 SERMs 53 familial hypercholesterolemia FH 53 Lu AA# 53 sulodexide 53 Altrazeal ® 53 delta gamma agonist 53 Fabry Disease 53 neurology immunology 53 neuroprotective properties 53 thrombophilia 53 hyperglycaemia 53 oral PTH 53 vildagliptin 53 zileuton CR 53 Homspera TM 53 torezolid phosphate 53 cyclophilin inhibitors 53 metformin sulfonylurea 53 pramlintide 53 Factor VIIa 53 metabolic syndrome MetS 53 orally inhaled migraine 53 antiemetics 53 gastroenterology neurology 53 Myelodysplastic syndromes MDS 53 VeraTag assays 53 Valdoxan 53 ophthalmologic disorders 53 oncology infectious diseases 53 OnDose TM 53 Elocalcitol 53 REMOXY ® 53 therapeutic monoclonal antibody 53 JAK inhibitor 53 beta interferons 53 Aceon 53 antithrombotic agents 53 diabetic dyslipidemia 53 IPL# 53 CYT# potent vascular disrupting 53 carotid atherosclerosis 53 Cardiometabolic 53 NUVIGIL 53 Azedra 53 HCV polymerase inhibitors 53 tolerability profiles 53 GKAs 53 TACI Ig 53 muraglitazar 53 atherosclerotic cardiovascular 53 Trofex 53 bardoxolone 53 antithrombotic 53 A3 adenosine receptor 53 inflammatory biomarkers 53 nicotinic alpha 7 53 TRV# [001] 53 overactive bladder syndrome 53 DPP4 inhibitor 53 osteoarthritis rheumatoid arthritis 53 Guanilib 53 paroxetine Paxil 53 AEGR 53 serum lipids 53 urolithiasis 53 Med eMonitor System 53 CobaCyte 53 vascular endothelial dysfunction 53 recombinant plasma 53 CYT# novel 53 immuno inflammatory 53 biochemical abnormalities 53 neurology urology 53 proliferative diseases 53 OHR/AVR# 53 proliferator activated receptor 52 glycosylated hemoglobin HbA1c 52 Neulasta ® 52 intranasal formulation 52 opioid induced 52 TTR amyloidosis 52 recurrent herpes labialis 52 epigenetic therapies 52 beta secretase inhibitors 52 vascular disrupting agents 52 REMINYL ® 52 protein kinase inhibitors 52 Xcytrin R 52 NNRs 52 tubulin inhibitor 52 Alequel 52 CIPN 52 dermaceutical 52 prospective multicenter study 52 albiglutide 52 pharmacodynamic markers 52 tezampanel NGX# 52 ophthalmics 52 exploratory endpoints 52 PREOS R 52 multiple sclerosis rheumatoid arthritis 52 eTag assays 52 thromboembolic disease 52 lixivaptan 52 ALTROPANE 52 invasive candidiasis 52 diabetic kidney 52 elevated LDL cholesterol 52 KL4 surfactant 52 allergic rhinitis hay fever 52 selective S#P# receptor agonist 52 Bendavia 52 etiological 52 metabolite identification 52 prostate carcinogenesis 52 haematologic 52 pramlintide metreleptin 52 SinuNase ™ 52 YONDELIS 52 plasma lipids 52 Clonicel 52 Sudhir Agrawal D.Phil 52 torsemide ER 52 renin inhibitors 52 acadesine 52 novel peptide therapeutics 52 Aviptadil 52 atherosclerotic vascular disease 52 Nanobodies ® 52 RNA antagonists 52 systolic hypertension 52 neuropathies 52 Myocet 52 Davunetide 52 melanocortin receptor 52 nitric oxide donating 52 insulin sensitizing 52 Dalbavancin 52 sibutramine Meridia 52 SUTENT ® 52 GFT# 52 AA Amyloidosis 52 SIRT1 activators 52 gastrin analogue TT 52 dyslipidemia hypertension diabetes 52 Oral NKTR 52 Aganocide 52 Adnectin 52 ostarine 52 INOmax R 52 Inc. OTCBB AKES 52 psoriasis rheumatoid arthritis 52 Nasulin TM 52 Lixivaptan 52 cardiology oncology 52 neurodegenerative diseases oncology 52 Phase IIb clinical trials 52 Friedreich Ataxia FRDA 52 cardiovascular morbidity 52 neurotherapy 52 Pseudomonas aeruginosa infections 52 anticoagulant reversing agent 52 nonalcoholic steatohepatitis NASH 52 PsychoGenics 52 dietary interventions 52 Syndax Pharmaceuticals Inc. 52 coagulation disorders 52 Anavex #-# 52 Tasimelteon 52 hereditary emphysema 52 ADME 52 biobetter 52 canakinumab 52 adenosine A2A 52 molecular biomarkers 52 Albugon 52 Pioglitazone 52 adrenergic regulation 52 oncolytic virus therapies 52 Detrol Detrol LA 52 SMT C# 52 Spiegelmer 52 Nasulin ™ 52 Personalized Immunotherapy 52 inherited metabolic disorders 52 neurology cardiology 52 anti infective 52 headache nausea dizziness 52 antisense inhibitors 52 T2DM 52 immunologic diseases 52 opioid bowel dysfunction 52 LEVADEX ™ 52 TPI ASM8 52 neurocognitive deficits 52 OREXIGEN 52 RGB # 52 vosaroxin 52 EMPOWER ™ 52 CaPre TM 52 haemostasis 52 Shigamabs ® 52 Ceflatonin R 52 Phase Ib study 52 hypercholesterolemic patients 52 alagebrium 52 ARIKACE ™ 52 investigational monoclonal antibody 52 pharmacogenetic tests 52 angiographic outcomes 52 CVD cardiovascular disease 52 Hedgehog agonist 52 Elagolix 52 oncology neuroscience 52 arterial thrombosis 52 AFFiRiS 52 endocrine disorders 52 P#X# antagonist 52 bicifadine 52 Noscira 52 prokinetic agent 52 nucleoside tide 52 ESBA# 52 Gaboxadol 52 Kinase inhibitors 52 Synavive ™ 52 neurovascular diseases 52 ALN TTR 52 GenPath 52 OraTest R 52 pharmacological therapy 52 Magnesium deficiency 52 genitourinary cancers 52 allosteric modulation 52 HIV integrase inhibitors 52 BiTE 52 Dynogen 52 CRLX# 52 Diamyd ® 52 commercializing therapeutic 52 oral salmon calcitonin 52 DVT PE 52 pathophysiological mechanisms 52 COPD asthma 52 neuropsychiatric symptoms 51 anticancer therapeutics 51 bardoxolone methyl 51 glitazones 51 Zybrestat 51 neurosensory 51 potent antiproliferative 51 neuro degenerative diseases 51 Nanobodies 51 preclinical efficacy 51 losartan Cozaar 51 subclinical atherosclerosis 51 Cardio Vascu Grow 51 torcetrapib atorvastatin 51 ESTRASORB 51 TH# [003] 51 Icatibant 51 lipid abnormalities 51 DermTech International 51 zanolimumab 51 Nocturia 51 inflammation metabolic disorders 51 Hepatitis C Virus HCV 51 potentially modifiable 51 XmAb 51 immunodiagnostics 51 Aurexis 51 NTx ® -# 51 clinically meaningful reductions 51 beta blockers ACE inhibitors 51 systemic amyloidosis 51 triphendiol 51 tetrabenazine 51 vitro pharmacology 51 Haptoglobin 51 QuatRx 51 postapproval 51 neuroscience autoimmune 51 diabetic neuropathic pain 51 Combivir Kivexa 51 Aryplase 51 GAMMAGARD 51 BrachySil TM 51 symptomatic neurogenic orthostatic hypotension 51 urate lowering 51 Incretin mimetics 51 CB2 receptor 51 extrapyramidal symptoms 51 mertansine 51 cognitive impairment associated 51 novel therapeutic antibodies 51 CDP# 51 opioid induced bowel dysfunction 51 MKC# MKC# PP 51 Cardiovascular Diabetes 51 therapeutics 51 IL# PE#QQR 51 muscarinic receptor agonist 51 vinca alkaloid 51 orthobiologic 51 GRN# 51 Protexia ® 51 MKC# MT 51 vidofludimus 51 Cortex AMPAKINE 51 hemoglobinopathies 51 IMiDs R 51 teriflunomide 51 lipid lowering 51 GERD migraine headaches 51 Zemplar Capsules 51 pharmacokinetic pharmacodynamic 51 hyperinsulinemia 51 pathophysiological processes 51 anti infectives cardiovascular 51 LDL cholesterol lowering 51 Exelixis compounds 51 renin inhibition 51 OXIGON TM 51 ATL# [002] 51 chemical entities NCEs 51 Heavy snorers 51 novel anticancer 51 BioFocus DPI Galapagos 51 metabolic dysfunction 51 antipsychotic induced 51 TMS Therapy 51 immunotherapeutics 51 GPCR targets 51 ophthalmology dermatology cardiovascular disease 51 chronic periodontitis 51 Elisabeth Lindner CEO 51 neurodevelopmental disabilities 51 EndoTAG TM -1 51 Dysmenorrhea 51 Epigenomics proprietary 51 Triapine R 51 PORxin TM 51 Aggrastat 51 non selective NSAIDs 51 BioSante LibiGel Phase III 51 anticancer compound 51 skin sterol 51 Syntonix 51 Triolex 51 XmAb ® 51 Onalta TM 51 herpetic keratitis 51 radezolid 51 neurogenic orthostatic hypotension 51 pharmacological approaches 51 tranilast 51 oncologic 51 ophthalmic diseases 51 forodesine 51 ProSavin 51 GSK# [002] 51 Phase IIIB IV 51 dysglycemia 51 PDE7 inhibitors 51 novel anti infective 51 systemic fungal infections 51 TÎ ² 4 51 metabolic disturbances 51 Dapagliflozin 51 sapacitabine CYC# 51 systemic lupus erythematosus 51 EndoTAG 51 lipid lowering therapies 51 PI3K inhibitors 51 DU #b 51 plasma lipid 51 antiphospholipid syndrome 51 investigational humanized monoclonal antibody 51 improves glycemic 51 Perforomist ™ Inhalation Solution 51 PRTX 51 Onconase 51 HQK 51 Zenvia ™ 51 Alexza Staccato 51 alvespimycin 51 ACTOS ® 51 equine osteoarthritis 51 fibrotic diseases 51 sirtuin activators 51 preclinically 51 SARMs 51 URG# 51 diagnostic prognostic 51 WILEX 51 Cachexia 51 NAGS deficiency 51 Ketotransdel 51 Nanobody R 51 nonpharmacologic 51 HuMax TAC 51 ghrelin antagonist 51 senicapoc 51 Psoriatic arthritis 51 Nonalcoholic fatty liver 51 efficacy tolerability 51 HIV lipodystrophy 51 dentin hypersensitivity 51 neuroinflammatory diseases 51 Cathepsin S 51 urology oncology 51 MabThera rituximab 51 rosiglitazone maleate 51 EECP ® therapy 51 XP# XP# 51 Plenaxis TM 51 faropenem 51 arterial calcification 51 REMOXY R 51 Desmoteplase 51 pulmonary hypertension PH 51 ophthalmology dermatology 51 pharmacogenetics 51 Cholestagel 51 Atelvia 51 vascular disorders 51 multi factorial diseases 51 lumiliximab 51 elevated homocysteine 51 multicenter trials 51 CCX# 51 R#/MEM # 51 macrovascular complications 51 ReN# therapy 51 HuLuc# 51 Itopride 51 CINQUIL 51 Starlix 51 David Cassak 51 nitric oxide donating prostaglandin 51 breast endometrial 51 TBC# 51 Epanova 51 ABILIFY ® 51 Ischemic heart 51 metabolics 51 Bioaccelerate compounds under 51 Hyperlipidemia 51 Pancreate 51 autonomic dysfunction 51 Phase IIb III 51 P#X# 51 CVBT #H 51 tezampanel 51 JANUMET 51 Cancidas 51 CRD5 51 idiopathic intracranial hypertension 51 fibrosis oncology 51 rivastigmine Exelon 51 Elevated triglycerides 51 glitazone class 51 IMiDs ® 51 SoluBest 51 heterozygous FH 51 Alzheimer Disease AD 51 enzastaurin 51 ocular inflammatory 51 Drug Repositioning 51 proliferative diabetic retinopathy 51 NXL# 51 pulmonary arterial hypertension PAH 51 Nasdaq PARD biopharmaceutical 51 cartilage degeneration 51 neuro vascular 51 NEUGENE R 51 cardiac conduction 51 PROSTVAC TM 51 postoperative ileus POI 51 dermatological disorders 51 Stapled Peptide 51 serum phosphate 51 targeted radiotherapeutic 51 potency selectivity 51 inhaled AAT 51 Cloretazine R 51 lipid particle 51 Pharma Medica 51 PROactive study 51 Evoltra ® 51 Zoraxel 51 NASDAQ FLML 51 SLx 51 abnormal lipid 50 POSIDUR TM ELADUR TM 50 AQ4N 50 rheumatic disorders 50 NeuVax 50 Tovaxin ® 50 Major Depressive Disorder MDD 50 Alzhemed TM 50 erythropoietic 50 Combo Stent 50 HIV HCV coinfected 50 sertraline Zoloft 50 subclinical disease 50 non cirrhotic portal 50 PRT# 50 Proellex TM 50 dietary antioxidants 50 Aplidin 50 pharmacological chaperone 50 dacetuzumab 50 Posiphen TM 50 Ampakine compounds 50 cardiotoxic effects 50 BHT DNA 50 Diabetic nephropathy 50 eculizumab therapy 50 cardiovascular disease 50 variant angina 50 Applied NeuroSolutions 50 Unit Dose Budesonide 50 PDE7 50 Panzem R 50 mGluR2 50 insulin sensitizers 50 hyperhomocysteinemia 50 type2 diabetes 50 Veronate 50 opioid induced constipation 50 anti infective treatments 50 Radezolid 50 Kosan dependence 50 renal diseases 50 mecarbil 50 vascular disease 50 Lp PLA 2 50 etiologic factors 50 Meta analyzes 50 abnormal glucose tolerance 50 synthetic cannabinoid compounds 50 antidiabetic medication 50 TG# [003] 50 LNP formulations 50 biased ligand 50 punctal plug drug 50 Lp PLA2 50 pharmacokinetic PK study 50 RIGScan CR 50 myeloproliferative disorders 50 preclinical compounds 50 NASDAQ CYTR biopharmaceutical 50 ischemic cardiovascular 50 Cutanea 50 rheumatoid arthritis thrombocytopenia 50 Sulonex TM 50 endocrine metabolic 50 HepeX B 50 mGluR5 antagonists 50 Cogane 50 visilizumab 50 inhalation toxicology 50 validating biomarkers 50 radiotherapeutic 50 neuroactive 50 Bucindolol 50 cathepsin K inhibitor 50 Nonalcoholic Fatty Liver Disease 50 Osteoarthritis OA 50 antiphospholipid syndrome APS 50 Novartis Diovan 50 tramiprosate 50 antiplatelet therapies 50 ORE# 50 gastrointestinal motility 50 SRBD 50 Surfaxin LS 50 Inc. Nasdaq NLTX 50 Carbamazepine 50 oxypurinol 50 tizanidine hydrochloride short 50 Renal Cell Carcinoma RCC 50 omecamtiv mecarbil 50 favorable pharmacokinetic profile 50 DPX Survivac 50 Peripheral Arterial Disease 50 Aricept donepezil 50 teduglutide 50 abdominal adiposity 50 Leber Hereditary Optic Neuropathy 50 glucocorticoid therapy 50 thromboembolic 50 irritability insomnia 50 immunosuppressive therapies 50 Phase Ib II 50 Cardiovascular Risk 50 specialty pharma 50 antimitotic 50 methylnaltrexone 50 molecular imaging radiopharmaceuticals 50 Onalta 50 Src inhibitors 50 urological diseases 50 atherothrombotic disease 50 neurology dermatology 50 Melior Discovery 50 antiarrhythmic drug 50 Prosaptide 50 Vilazodone 50 DNA methylation biomarkers 50 prognostic markers 50 ChronVac C R 50 antiplatelet medications 50 Fx #A 50 Vimpat lacosamide 50 Biolipox 50 neuro developmental disorders 50 cachexia 50 recurrent miscarriage 50 cardiac biomarkers 50 Anturol TM 50 co morbidities 50 biostatistical analysis 50 RLY# 50 osteoporosis arthritis 50 cardiovascular disorders 50 Chrysalin 50 pediatric bipolar disorder 50 Endotis 50 reslizumab 50 degenerative disorders 50 Ph.D. Targacept 50 THR beta agonist 50 novel peptide 50 unpartnered 50 pregabalin Lyrica 50 thiazolidinediones TZDs 50 ancrod 50 cardiovascular diseases 50 PDX pralatrexate 50 Uvidem 50 Oasmia 50 mixed hyperlipidemia 50 potassium sparing diuretics 50 antiobesity 50 Female Athlete Triad 50 severely immunosuppressed 50 NSAID induced 50 diabetic gastroparesis 50 Severe Primary IGFD 50 antiarrhythmic 50 oncology 50 Hp2 2 50 TRO# 50 Parkinson disease Alzheimer disease 50 lupus nephritis 50 novel oral anticoagulant 50 castrate resistant prostate cancer 50 oral picoplatin 50 overactive bladder symptoms 50 stage hypoxia activated 50 TLR9 agonist 50 anorexia nervosa bulimia